NVCR - ノボキュア (NovoCure Limited) ノボキュア

 NVCRのチャート


 NVCRの企業情報

symbol NVCR
会社名 NovoCure Ltd (ノボキュア)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノボキュア(NovoCure Limited)は商業段階の腫瘍学会社である。同社は固形癌細胞分裂を破壊するために特定の周波数に調整された電場を使用するTTFieldsと呼ばれる療法を中心とする癌治療法の開発に従事する。TTFieldsはグリア芽腫(GBM)の治療に使用され、臨床パイプラインを通じて複数の固形腫瘍適応症におけるTTFieldのプログラム検査を進めるために使用される。GBMの臨床的・商業的発展に加えて、TTFieldは脳転移、非小細胞肺癌(NSCLC)、膵臓癌、卵巣癌および中皮腫におけるTTFieldの使用を評価する臨床試験を計画または実施している。TTFieldは、ポータブルな医療機器を通じて提供される。完全な送達システムは、継続的な癌治療を受けながら患者が日々の活動に慣れることができるように設計され、携帯用電界ジェネレータ、トランスデューサアレイ、充電式バッテリ、アクセサリーを含む。   ノボキュアは英国の医療機器メ―カ―。主に固形がん腫瘍の治療向け医療機器の開発に従事する。同社開発の「TTFields」は非侵襲性の腫瘍治療電場システムで、細胞分裂阻止の治療電場を発生させ通常のプロセスを阻害し、がん細胞を死滅する。一般的ながん治療である手術、放射線治療、抗がん剤治療に合わせ、更なる治療法を開発する。本社は英国ジャ―ジ―島。   
本社所在地 No. 4 The Forum Grenville Street St. Helier Jersey JE2 4UF GBR
代表者氏名 William F. Doyle ウィリアムF.ドイル
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +44 1534-75-6700
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 495人
url www.novocure.com
nasdaq_url https://www.nasdaq.com/symbol/nvcr
adr_tso
EBITDA EBITDA(百万ドル) -21.49100
終値(lastsale) 48.2
時価総額(marketcap) 4477903392
時価総額 時価総額(百万ドル) 3966.939
売上高 売上高(百万ドル) 217.40900
企業価値(EV) 企業価値(EV)(百万ドル) 3897.179
当期純利益 当期純利益(百万ドル) -93.47700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novocure Ltd revenues increased 55% to $113.6M. Net loss decreased 8% to $36.2M. Revenues reflect Europe_Middle East_Africa (EMEA) (Region) segment increase from $12.6M to $32.4M United States segment increase of 32% to $79.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.40.

 NVCRのテクニカル分析


 NVCRのニュース

   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   Insider Selling: NovoCure Limited (NASDAQ:NVCR) CEO Sells 207,910 Shares of Stock  2020/12/25 09:06:45 Watchlist News
NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 207,910 shares of NovoCure stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $157.39, for a total value of $32,722,954.90. Following the transaction, the chief executive officer now directly owns 301,587 shares in the company, valued at approximately $47,466,777.93. The […]
   Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma  2020/12/14 06:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced national reimbursement in Switzerland for Optune in combination with temozolomide for the treatment of newly diagnosed GBM.
   J.P. Morgan Stick to Their Hold Rating for NovoCure Ltd  2020/12/11 09:11:42 Investing.com
J.P. Morgan Stick to Their Hold Rating for NovoCure Ltd
   Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference  2020/11/25 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020.
   Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference  2020/11/25 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020.
   Novocure : Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting | MarketScreener  2020/11/19 13:07:02 MarketScreener
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors … | November 19, 2020
   Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting  2020/11/19 13:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.
   Novocure Receives CE Mark for NovoTTF-100L™ System  2020/11/11 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure has received the CE mark for the NovoTTF-100L system, enabling commercialization of the device to treat MPM in the E.U. and Switzerland.
   Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks  2020/11/09 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced the closing of a new $150 million revolving credit facility with a syndicate of relationship banks.
   Novocure : Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting | MarketScreener  2020/11/19 13:07:02 MarketScreener
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors … | November 19, 2020
   Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting  2020/11/19 13:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.
   Novocure Receives CE Mark for NovoTTF-100L™ System  2020/11/11 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure has received the CE mark for the NovoTTF-100L system, enabling commercialization of the device to treat MPM in the E.U. and Switzerland.
   Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks  2020/11/09 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced the closing of a new $150 million revolving credit facility with a syndicate of relationship banks.
   How to Play NovoCure Stock Right Now  2020/11/04 16:26:32 The Street RealMoney
How to Play NovoCure Stock Right Now…NVCR

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノボキュア NVCR NovoCure Limited)

 twitter  (公式ツイッターやCEOツイッターなど)